保留比值受损肺功能与气道阻塞的肺癌风险:UK Biobank研究
该研究基于UK Biobank 267,222名基线肺功能正常且无癌症史的参与者,分析PRISm、轻度和中重度COPD与肺癌发病风险的关系。中位随访13年,共发现2,058例肺癌。校正混杂因素后,PRISm组肺癌风险显著升高(HR 1.59,95%CI 1.38-1.82),轻度和中重度COPD组风险亦升高。
要点
- PRISm与肺癌风险独立相关,校正后HR为1.59。
- 轻度COPD肺癌风险HR为1.75,中重度COPD为2.92。
- PRISm人群需加强风险分层和早期筛查策略。
核心结论
- PRISm与肺癌风险独立相关,风险高于正常肺功能者。
- 中重度COPD肺癌风险最高,轻度COPD和PRISm风险居中。
研究设计与样本
- 基于UK Biobank 267,222名基线有肺功能且无癌症史的参与者。
- 按肺功能分为正常、PRISm、轻度COPD和中重度COPD。
- 通过国家癌症登记链接识别肺癌发病,采用Cox比例风险和Fine-Gray竞争风险模型。
主要发现
- 中位随访13年,共发现2,058例肺癌。
- 与正常肺功能相比,PRISm组肺癌校正HR为1.59(95%CI 1.38-1.82)。
- 轻度COPD组校正HR为1.75(95%CI 1.51-2.02)。
- 中重度COPD组校正HR为2.92(95%CI 2.62-3.25)。
- 竞争风险模型中PRISm组sHR为1.55(95%CI 1.35-1.79),结果一致。
关键数值与推荐
- PRISm定义为FEV1/FVC≥0.70且FEV1<80%预计值。
- 轻度COPD定义为FEV1/FVC<0.70且FEV1≥80%预计值。
- 中重度COPD定义为FEV1/FVC<0.70且FEV1<80%预计值。
临床怎么用
- 对PRISm人群应提高肺癌风险意识,考虑纳入风险分层和早期筛查评估。
- COPD患者同样需关注肺癌风险,尤其中重度COPD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preserved ratio impaired spirometry (PRISm) has emerged as a distinct pulmonary pattern with potential clinical significance, but its association with lung cancer risk remains unclear. RESEARCH QUESTION: In the same way that COPD increases the risk of lung cancer, could PRISm be a risk factor for developing lung cancer? STUDY DESIGN AND METHODS: We analyzed data from 267,222 UK Biobank participants who underwent spirometry at baseline and had no history of cancer before enrollment. Lung function was categorized as normal, PRISm (FEV1 to FVC ratio ≥ 0.70 and FEV1 < 80% predicted), mild COPD (FEV1 to FVC ratio < 0.70 and FEV1 ≥ 80%), and moderate to severe COPD (FEV1 to FVC ratio < 0.70 and FEV1 < 80%). Patients with incident lung cancer were identified through linkage to national cancer registries. Cox proportional hazards and Fine-Gray competing risk models were used to estimate hazard ratios (HRs) and subdistribution HRs (sHRs), adjusting for confoundings. RESULTS: During a median follow-up of 13 years, 2,058 patients with incident lung cancer were identified. In multivariate models, the adjusted HR for lung cancer was 1.59 (95% CI, 1.38-1.82) in the PRISm group, 1.75 (95% CI, 1.51-2.02) in the mild COPD group, and 2.92 (95% CI, 2.62-3.25) in the moderate to severe COPD group compared with that among individuals with normal spirometry findings. Results from the competing risk model were consistent, with an sHR of 1.55 (95% CI, 1.35-1.79) in the PRISm group. INTERPRETATION: Our results show that PRISm is associated independently with an increased risk of lung cancer. It is necessary to improve risk stratification and potential early screening strategies in populations with PRISm.
引用
- Choi JY, Rhee CK, Lee J, et al. Lung Cancer Risk in Preserved Ratio Impaired Spirometry and Airway Obstruction: A UK Biobank Study. Chest. 2025. PMID: 41072905. doi:10.1016/j.chest.2025.09.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。